Abstract
The standard gold care medications for benign prostatic hyperplasia (BPH) are the alpha-1-adrenergic antagonists, they are an effective medications and are generally well tolerated. However, at this time, no data have been published concerning the development of severe rhinorrhea with a great impact on quality of life in patients treated with alpha-1-adrenergic antagonists. We report two men with BPH treated with two different alpha-adrenergic antagonists; alfuzosin and doxazocin. The naranjo quality scale documented a probable adverse drug reaction (score 7) between rhinorrhea and treatmenr with alpha-1-adrenergic antagonists. In conclusion we reported that alpha-1-adrenergic antagonists are able to induce rhinorrhea in patients with BPH.
Keywords: Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS).
Current Drug Safety
Title:Alpha-1 Adrenergic Antagonists Induced Severe Rhinitis in Patients with Benign Prostatic Hyperplasia
Volume: 9 Issue: 2
Author(s): Eduardo Shahar, Laila Nassar, Eynat Kedem and Gammal Hassoun
Affiliation:
Keywords: Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS).
Abstract: The standard gold care medications for benign prostatic hyperplasia (BPH) are the alpha-1-adrenergic antagonists, they are an effective medications and are generally well tolerated. However, at this time, no data have been published concerning the development of severe rhinorrhea with a great impact on quality of life in patients treated with alpha-1-adrenergic antagonists. We report two men with BPH treated with two different alpha-adrenergic antagonists; alfuzosin and doxazocin. The naranjo quality scale documented a probable adverse drug reaction (score 7) between rhinorrhea and treatmenr with alpha-1-adrenergic antagonists. In conclusion we reported that alpha-1-adrenergic antagonists are able to induce rhinorrhea in patients with BPH.
Export Options
About this article
Cite this article as:
Shahar Eduardo, Nassar Laila, Kedem Eynat and Hassoun Gammal, Alpha-1 Adrenergic Antagonists Induced Severe Rhinitis in Patients with Benign Prostatic Hyperplasia, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140527112408
DOI https://dx.doi.org/10.2174/1574886309666140527112408 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systemic Therapeutic Gene Delivery for Cancer: Crafting Paris Arrow
Current Gene Therapy Effect of the Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture
Current Hypertension Reviews Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms
Current Neuropharmacology Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?
Current Gene Therapy A Comprehensive Review on Phytochemistry and Pharmacological Effects of Stinging Nettle (Urtica dioica)
Current Traditional Medicine Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Pulmonary Arterial Hypertension
Current Vascular Pharmacology Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis
Current Vascular Pharmacology C. elegans as a Genetic Model System to Identify Parkinson's Disease- Associated Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Urocortins: Take Them to Heart
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry